Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma

BACKGROUND: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhuo-miao, Tang, Zi-Qing, Xu, Zhe, Zhou, Qin, Li, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354521/
https://www.ncbi.nlm.nih.gov/pubmed/35937220
http://dx.doi.org/10.3389/fpubh.2022.947375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354521/
https://www.ncbi.nlm.nih.gov/pubmed/35937220
http://dx.doi.org/10.3389/fpubh.2022.947375

Ejemplares similares